NasdaqGS:AMLXPharmaceuticals
Amylyx Pharmaceuticals (AMLX) Could Be 5% Undervalued After Second Quarter Earnings
Amylyx Pharmaceuticals (AMLX) shares moved after the company reported second quarter 2026 results, which showed a net loss of US$43.42 million and basic loss per share from continuing operations of US$0.39.
See our latest analysis for Amylyx Pharmaceuticals.
The latest earnings update appears to have sharpened attention on Amylyx Pharmaceuticals, with the share price at US$24.19 and a 1-day share price return of 10.71%, building on a 30-day share price return of 33.13% and a 1-year total...